| Primary |
| Multiple Sclerosis |
81.2% |
| Product Used For Unknown Indication |
3.8% |
| Hypertension |
1.7% |
| Depression |
1.7% |
| Pain |
1.5% |
| Blood Pressure |
1.3% |
| Muscle Spasms |
1.3% |
| Anxiety |
1.1% |
| Blood Cholesterol |
0.7% |
| Diabetes Mellitus |
0.7% |
| Fatigue |
0.7% |
| Neuralgia |
0.7% |
| Relapsing-remitting Multiple Sclerosis |
0.6% |
| Sleep Disorder |
0.5% |
| Migraine |
0.5% |
| Bladder Disorder |
0.4% |
| Cardiac Disorder |
0.4% |
| Headache |
0.4% |
| Muscle Spasticity |
0.4% |
| Asthma |
0.3% |
|
| Paraesthesia |
12.9% |
| Weight Decreased |
11.2% |
| Multiple Sclerosis Relapse |
8.7% |
| Nausea |
7.6% |
| Vomiting |
6.4% |
| Alopecia |
5.3% |
| Diarrhoea |
5.1% |
| Pain |
4.7% |
| Urinary Tract Infection |
4.0% |
| Drug Dose Omission |
3.9% |
| Rash |
3.9% |
| Vision Blurred |
3.9% |
| Multiple Sclerosis |
3.6% |
| Visual Impairment |
3.4% |
| White Blood Cell Count Decreased |
3.0% |
| Headache |
2.6% |
| Pain In Extremity |
2.6% |
| Wrong Technique In Drug Usage Process |
2.5% |
| Pruritus |
2.3% |
| Adverse Event |
2.2% |
|
| Secondary |
| Multiple Sclerosis |
80.1% |
| Hypertension |
2.5% |
| Pain |
2.5% |
| Blood Pressure |
2.4% |
| Muscle Spasms |
2.1% |
| Depression |
1.5% |
| Relapsing-remitting Multiple Sclerosis |
1.0% |
| Fatigue |
0.7% |
| Muscle Relaxant Therapy |
0.7% |
| Neuralgia |
0.7% |
| Postoperative Care |
0.7% |
| Blood Triglycerides |
0.6% |
| Diabetes Mellitus |
0.6% |
| Gait Disturbance |
0.6% |
| Product Used For Unknown Indication |
0.6% |
| Sleep Disorder |
0.6% |
| Bone Disorder |
0.4% |
| Dyspepsia |
0.4% |
| Gastrooesophageal Reflux Disease |
0.4% |
| Hyperlipidaemia |
0.4% |
|
| Weight Decreased |
16.3% |
| Paraesthesia |
12.1% |
| Vomiting |
9.9% |
| White Blood Cell Count Decreased |
7.1% |
| Urinary Tract Infection |
5.7% |
| Wrong Technique In Drug Usage Process |
5.7% |
| Nausea |
5.0% |
| Multiple Sclerosis Relapse |
4.3% |
| Pain |
4.3% |
| Vision Blurred |
4.3% |
| Sensation Of Heaviness |
3.5% |
| Visual Acuity Reduced |
3.5% |
| Drug Dose Omission |
2.8% |
| Multiple Sclerosis |
2.8% |
| Headache |
2.1% |
| Pneumonia |
2.1% |
| Pollakiuria |
2.1% |
| Urinary Incontinence |
2.1% |
| Urinary Retention |
2.1% |
| Visual Impairment |
2.1% |
|
| Concomitant |
| Multiple Sclerosis |
82.0% |
| Product Used For Unknown Indication |
14.0% |
| Gait Disturbance |
2.0% |
| Sleep Disorder |
2.0% |
|
| Sinusitis |
9.1% |
| Vomiting |
9.1% |
| Alopecia |
4.5% |
| Drug Withdrawal Convulsions |
4.5% |
| Fatigue |
4.5% |
| Gait Disturbance |
4.5% |
| Influenza Like Illness |
4.5% |
| Liver Disorder |
4.5% |
| Multiple Sclerosis Relapse |
4.5% |
| Muscle Spasms |
4.5% |
| Muscle Tightness |
4.5% |
| Pain |
4.5% |
| Skin Hypertrophy |
4.5% |
| Skin Irritation |
4.5% |
| Skin Necrosis |
4.5% |
| Skin Ulcer |
4.5% |
| Stress |
4.5% |
| Syncope |
4.5% |
| Tremor |
4.5% |
| Visual Impairment |
4.5% |
|
| Interacting |
| Anxiety |
50.0% |
| Multiple Sclerosis |
50.0% |
|
|
